Screener
Tarsus Pharmaceuticals, Inc. TARS Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -8%+25.2pp | -9.5%+37.2pp | -15.7%+50.2pp | -23.9%+84.6pp | -33.2%+154pp | |
| Net margin | -7.7%+23.5pp | -9%+35.9pp | -14.7%+48.4pp | -22.2%+81.5pp | -31.1%+149pp | |
| Returns | ||||||
| Return on equity | -13.7%+17.8pp | -14%+20.0pp | -23.4%+31.4pp | -28.3%+31.2pp | -31.5%+43.6pp | |
| Return on invested capital | -18.2%+25.4pp | -17.8%+44.5pp | -32.3%+86.3pp | -40%+143pp | -43.5%+104pp | |
| Efficiency | ||||||
| Asset turnover | 1.1×+0.4× | 1×+0.4× | 1×+0.4× | 0.8×+0.4× | 0.7×+0.4× | |
| Liquidity | ||||||
| Current ratio | 3.2×-2.1× | 3.7×-1.8× | 3.9×-0.6× | 4.3×-1.1× | 5.3×-1.8× | |
| Leverage | ||||||
| Debt-to-equity | 0.3×0.0× | 0.3×0.0× | 0.2×-0.1× | 0.2×-0.1× | 0.2×-0.1× | |
| Per Share | ||||||
| Book value per share | $7.99+1.8% | $8.12-6.7% | $8.22+37.7% | $7.86+27.1% | $7.85+17.7% | |
| Valuation | ||||||
| Market capitalization | $2.87B+63.9% | $2.99B+41.1% | $3.48B+64.2% | $2.51B+102% | $1.74B+81.3% | |
| Price / sales | 4.7×-1.2× | 5.6×-3.5× | 7.7×-3.9× | 6.9×-2.7× | 5.9×-5.6× | |
| Price / book | 8.3×+3.0× | 8.6×+2.4× | 10.1×+0.7× | 7.5×+2.2× | 5.2×+1.4× |
FAQ
- What are Tarsus Pharmaceuticals, Inc.'s profit margins?
- Tarsus Pharmaceuticals, Inc. (TARS) runs a 79.8% gross margin and a -8.0% operating margin, with a -7.7% net margin.
- Where do Tarsus Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Tarsus Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
